Person:
Kwong, Gabriel A.

Associated Organization(s)
ORCID
ArchiveSpace Name Record

Publication Search Results

Now showing 1 - 2 of 2
  • Item
    Point-of-Care Diagnostics via DNA-Based Isothermal Amplification and Paper Test
    (Georgia Institute of Technology, 2020-05-13) Kwong, Gabriel A.
    The current SARS-CoV-2 pandemic has highlighted the importance for rapid testing to track and contain the outbreak of infectious diseases. Current tests rely on RT-qPCR which requires a thermocycler and limits point-of-care (POC) use. POC tests that can amplify signals without specialized instrumentation could be deployed for rapid screening and reach a broader segment of the population. Here we will highlight strategies for isothermal amplification to allow major classes of biomarkers – including nucleic acids, proteins, and cells – to be detected with minimal sample processing. Central to our strategy is taking advantage of enzymatic turnover, such as with proteases or Cas12a, to amplify detection signals. We aim to adapt these methods with paper-based assays to allow visualization of test results by eye. These strategies are generalization to a broad range of diseases to increase access to POC testing.
  • Item
    Nanotechnology for Ultrasensitive and Noninvasive Diagnostics
    (Georgia Institute of Technology, 2015-01-27) Kwong, Gabriel A.
    Biomarkers are increasingly important in the clinical management of complex diseases, yet our ability to discover new biomarkers remains limited by our dependence on endogenous biomolecules. Here I describe the development of “synthetic biomarkers” comprising protease-sensitive nanoparticles that perform three functions following administration: they target sites of disease, sense dysregulated protease activities, and release reporters into the host urine as indicators of disease. These urinary reporters are mass-encoded to allow multiplexed analysis by mass spectrometry, or functionalized with capture ligands to allow detection by low-cost paper tests in global health settings. By engineering nanoparticles to sense different proteases, I show that synthetic biomarkers may be used to noninvasively monitor liver fibrosis and reversal, detect dangerous pulmonary blood clots and detect cancer earlier compared to blood biomarkers. Synthetic biomarkers have the potential to significantly expand our repertoire of diagnostic nanomedicines, and may allow systems-level analysis of multi-enzymatic networks in health and disease.